BioVie Inc (BIVI)

6.11 +0.14  +2.35% NASDAQ Oct 28, 12:45 USD
View Full Chart
Price Chart
View All BIVI News

News

View All Events

Events

Date Type Description
11/05/2021 Earnings Results Q1 2022 Earnings Results
05/10/2021 Earnings Results Q3 2021 Earnings Results
01/29/2021 Earnings Results Q2 2021 Earnings Results
11/05/2020 Earnings Results Q1 2021 Earnings Results
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • Description: BioVie Inc is a company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is currently focused on developing and commercializing BIV201, a novel investigational approach to the treatment of ascites due to chronic liver cirrhosis. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism. The company recently acquired the assets of NeurMedix Inc including NE3107 that inhibits inflammatory activation of ERK and NFB.
  • URL: http://www.biovieinc.com
  • Investor Relations URL: https://www.biovieinc.com/investors/
  • HQ State/Province: California
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Small Cap/Blend
  • Next Earnings Release: Nov. 05, 2021
  • Last Earnings Release: May. 10, 2021
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.